EANS-Adhoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Molecular diagnostics

28.02.2011

Berlin, Germany, February 28, 2011 - Epigenomics AG (ISIN:
DE000A0BVT96) today signed an option agreement in colorectal cancer
blood testing with QIAGEN N.V. (ISIN: NL0000240000).

Under the terms of the agreement, QIAGEN receives an option to a
worldwide non-exclusive commercial license to Epigenomics'
proprietary mSEPT9 biomarker and DNA methylation technologies for the
detection of colorectal cancer in blood. The option can be exercised
by QIAGEN within the next two years. Furthermore, Epigenomics has
granted QIAGEN a research license to the mSEPT9 biomarker and the
technologies. Under this license, QIAGEN is currently developing a
novel sample preparation technology that meets the requirements for
the future broad implementation of methylation-based molecular
diagnostics, such as Septin9-targeted blood testing for the detection
of colorectal cancer, on QIAGEN's modular molecular testing platform
QIAsymphony. Epigenomics will support QIAGEN in the R&D phase through
know-how transfer and the collection of clinical specimens as
required.

Under the terms of the option agreement, Epigenomics will receive an
upfront payment from QIAGEN and will be reimbursed for any R&D
support and clinical specimens provided during the R&D phase. Upon
QIAGEN exercising the option Epigenomics would receive a further
license payment. Once QIAGEN commercializes a colorectal cancer blood
test based on Epigenomics' biomarkers and technology, Epigenomics
would be entitled to royalties on QIAGEN's net sales as well as
certain commercial milestones upon reaching specific revenue targets.

-End of Ad hoc-

Further Information

For further information please see the press release issued today by
Epigenomics AG at www.epigenomics.com.

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 0
pr@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade